... This specific type of antigen was named CD20. By 1990, Rituxan (rituximab) had been developed. Rituxan is an antibody that attaches to this CD20 antigen. This targeted approach meant that Rituxan killed more malignancies and fewer healthy cells. ...
The History of Leukemia Explained
... This specific type of antigen was named CD20. By 1990, Rituxan (rituximab) had been developed. Rituxan is an antibody that attaches to this CD20 antigen. This targeted approach meant that Rituxan killed more malignancies and fewer healthy cells. ...
... Rituximab is a monoclonal antibody — a man-made antibody that attaches to and blocks the protein CD20. Combining rituximab with cladribine often leads to better outcomes than the use of cladribine by itself.ImmunotherapyImmunotherapy treatments help boost the body’s immune system to kill cancer cells. ...
Hairy Cell Leukemia: Diagnosis and Treatment
... Rituximab is a monoclonal antibody — a man-made antibody that attaches to and blocks the protein CD20. Combining rituximab with cladribine often leads to better outcomes than the use of cladribine by itself.ImmunotherapyImmunotherapy treatments help boost the body’s immune system to kill cancer cells. ...
... Specific B-cell surface antigens such as CD19 and CD20, which are proteins on the outside of B cells, can also be used to distinguish Burkitt leukemia and lymphoma cells from other types of leukemias and lymphomas.A correct diagnosis is important for ensuring the right treatment. ...
Understanding Burkitt Leukemia
... Specific B-cell surface antigens such as CD19 and CD20, which are proteins on the outside of B cells, can also be used to distinguish Burkitt leukemia and lymphoma cells from other types of leukemias and lymphomas.A correct diagnosis is important for ensuring the right treatment. ...
... Some of these other proteins include CD20 and DBA.44. If your doctor tests your cells for TRAP, they may also test for these or other proteins using different immunohistochemical stains. Immunophenotyping helps determine what type of leukemia you have.Genetic TestsCancer cells often undergo many gene changes. ...
What Is the TRAP Protein in Hairy Cell Leukemia?
... Some of these other proteins include CD20 and DBA.44. If your doctor tests your cells for TRAP, they may also test for these or other proteins using different immunohistochemical stains. Immunophenotyping helps determine what type of leukemia you have.Genetic TestsCancer cells often undergo many gene changes. ...
... Rituximab attaches to a protein called CD20 found on B cells. Treatment plans combining rituximab and chemotherapy drugs may include: FCR — Fludara (fludarabine), Cytoxan (cyclophosphamide), Rituxan (rituximab) BR — Treanda (bendamustine) and rituximab Chemotherapy drugs often do not work well for people who have a mutation in the TP53 gene. ...
B-Cell Prolymphocytic Leukemia
... Rituximab attaches to a protein called CD20 found on B cells. Treatment plans combining rituximab and chemotherapy drugs may include: FCR — Fludara (fludarabine), Cytoxan (cyclophosphamide), Rituxan (rituximab) BR — Treanda (bendamustine) and rituximab Chemotherapy drugs often do not work well for people who have a mutation in the TP53 gene. ...
... This drug blocks a protein called CD20 that is found on B cells. Additionally, Blincyto (blinatumomab) and Besponsa (inotuzumab ozogamicin) are targeted therapy medications that can be used to treat refractory or relapsed B-cell ALL. Other targeted therapies are used to treat people who have Philadelphia chromosome-positive ALL. ...
B-Cell Acute Lymphoblastic Leukemia: Your Guide
... This drug blocks a protein called CD20 that is found on B cells. Additionally, Blincyto (blinatumomab) and Besponsa (inotuzumab ozogamicin) are targeted therapy medications that can be used to treat refractory or relapsed B-cell ALL. Other targeted therapies are used to treat people who have Philadelphia chromosome-positive ALL. ...
Join
Your Privacy Choices
